'Cerebral atrophy' diaporamas de présentation

New and Emerging Therapies in MS: Is It Time to Change the Status Quo?

Anne H. Cross, MD Professor of Neurology Washington University School of Medicine St. Louis, Missouri. New and Emerging Therapies in MS: Is It Time to Change the Status Quo?. Outline. How have our goals been altered by the new MS therapies? Balancing efficacy with safety

1.22k views • 100 slides

BRAIN

BRAIN. PHAKOMATOSIS. PHAKOMATOSIS. STURGE-WEBER SYNDROME VON HIPPEL-LINDAU DISEASE. STURGE-WEBER SYNDROME. Description:.

1.12k views • 83 slides

BRAIN

BRAIN. PHAKOMATOSIS. PHAKOMATOSIS. STURGE-WEBER SYNDROME VON HIPPEL-LINDAU DISEASE. STURGE-WEBER SYNDROME. Description:.

832 views • 83 slides

New Insights into Current MS Treatment

New Insights into Current MS Treatment NMSS 20th Annual Research Symposium Robert Shin, MD Maryland Center for MS Impact of MS Leading non-traumatic cause of disability in young adults 250,000 to 350,000 affected in US* National cost of nearly $10 billion per year* MS treatment 1990

826 views • 47 slides

Hydrogen Sulfide (H 2 S)

Hydrogen Sulfide (H 2 S). Hydrogen Sulfide - Overview. Colorless, irritating, flammable gas, heavier than air Rotten egg odor (concentrations > 0.5 ppm) Soluble in water, forming sulfuric acid. Hydrogen Sulfide - Overview. Commercial and industrial use Petroleum Viscose rayon Rubber

852 views • 22 slides

Cognitive impairment and recovery associated with episodic and chronic alcohol use amongst Aboriginal Australians, and the factors that influence continued use after treatment Kylie Dingwall & Dr Sheree Cairney. Brain atrophy, ventricular enlargement, widened sulci

325 views • 16 slides

Dementia

Dementia . So what does it look like?. So what do you think???.

353 views • 12 slides

347 views • 12 slides